Inspire(US:INSP) Globenewswireยท2025-11-11 14:11Core Viewpoint - Inspire Medical Systems, Inc. is facing a proposed class-action lawsuit for allegedly misleading investors regarding the commercial readiness and demand for its Inspire V sleep apnea device, leading to a significant stock decline [1][6]. Company Overview - Inspire Medical Systems, Inc. is under investigation by prominent investor rights law firm Hagens Berman for claims related to investor losses during the class period from August 6, 2024, to August 4, 2025 [2][3]. Allegations and Claims - The lawsuit asserts that Inspire provided repeated assurances about meeting all regulatory and commercial prerequisites for the Inspire V launch, while claiming high demand and successful commercial proceedings [3]. - Contrary to these assurances, the lawsuit claims that the Inspire V launch was a failure, with minimal initial demand due to customers being overstocked with the older Inspire IV devices [4]. - The complaint indicates that Inspire neglected essential steps to facilitate the new device's adoption by clinicians and payors [4]. Impact of the Launch - On August 4, 2025, Inspire disclosed that the launch faced an "elongated timeframe" due to undisclosed challenges, including incomplete training and onboarding at many centers [5]. - The company noted that while the CPT code for Inspire V was approved for Medicare patients, necessary software updates for claims processing were delayed until July 1, affecting billing capabilities [5]. - Demand for Inspire V was further hindered by the need for customers to deplete existing Inspire IV inventory, which is expected to continue impacting demand [6]. Financial Consequences - Following the disastrous launch, Inspire slashed its 2025 earnings guidance by 80%, projecting earnings of only $0.40 to $0.50 per share [6]. - The announcement led to a significant drop in Inspire's stock price, with shares falling by approximately 32%, or $42.04, the day after the news [6].